****************
At a public hearing held today at the European Parliament in Brussels,
EU governments were called upon to ensure that public funding in
research be primarily invested in meeting public needs and priorities,
including specific health needs of populations in developing
countries.
Affecting hundreds of millions, infectious diseases like HIV/AIDS,
malaria, tuberculosis and the most neglected diseases such as
leishmaniasis, Chagas disease, and sleeping sickness kill 35,000
people each day. Although basic scientific knowledge about these
diseases has progressed, there has been poor translation of this
knowledge into essential medicines that meet the needs of millions of
patients by being safe, effective, affordable, and easy-to-use.
In January this year, the Executive Board of the World Health
Organization (WHO) took the first step in addressing these priority
health needs by forwarding to the World Health Assembly (WHA) a
resolution proposed by Kenya and Brazil that calls for the WHO to
create a new global framework on research and development (R&D). This
proposal, which received support from a cross-party group of Members
of the European Parliament, will be considered for adoption at the WHA
in May.
"We welcome the EU parliament's support for a greater WHO role in
priority setting for research and development," said Dr. Tido von
Schoen-Angerer, Director for Research and Development at MSF's
Campaign for Access to Essential Medicines.
"Two major issues must be addressed by all governments: the
prioritization of needs-driven drug research and development as well
as sufficient and sustainable funding for this research," remarked Dr.
Els Toreele of the Drugs for Neglected Diseases initiative (DNDi).
"European governments must provide greater support for something real
to happen."
At the hearing today, a panel of scientists and medical professionals
urged European governments to provide greater political leadership
through the Seventh Framework Programme for European Research (FP7) to
ensure sustainable, increased global funding for health research and
to speed up the translation of scientific progress into effective
treatments for neglected patients most in need.
"Public leadership is needed to define needs and set up priorities for
neglected diseases R&D," said Bernard Pecoul, Executive Director of
DNDi. "FP7 should include the most neglected diseases in its
priorities, and some of the existing European mechanisms like the
EDCTP (European and Developing Countries Clinical Trials Partnership)
must broaden their mandate to include research on most neglected
diseases and further enable the transfer of technology to
disease-endemic countries. Stronger North-South and South-South
collaboration will help reduce the heavy disease burden of poorer
countries in the long run."
Based in Geneva, the Drugs for Neglected Diseases Initiative (DNDi) is
an independent, not-for-profit drug development initiative that aims
to develop new, improved, and field-relevant drugs for neglected
diseases such as leishmaniasis, human African trypanosomiasis, Chagas
disease, and malaria. DNDi's partners include MSF, Institut Pasteur,
and public sector research institutions from Brazil, Kenya, Malaysia,
and India; along with the WHO's Tropical Diseases Research program
acting as a permanent observer. With a current portfolio of 20
projects in various stages of drug research and development, DNDi also
works to raise awareness about the need for greater R&D for neglected
diseases and strengthens existing research capacity in disease-endemic
countries. For further information:
http://www.dndi.org
To learn more about the public hearing, click here:
http://www.epha.org/a/2114
Drugs for Neglected Diseases initiative
1 Place St Gervais
1201 Geneva
Switzerland
http://www.dndi.org
Please support the R&D Appeal urging governments to boost innovation
for neglected diseases.-sign up at
http://www.researchappeal.org
Online at:
http://www.medicalnewstoday.com/medicalnews.php?newsid=37407&nfid=crss
---------
Stay Connected - Speak your world!
A posting from: Keep the Promise: Start Making Sense!